Many patients with stages I to IIIA NSCLC are eligible for surgery followed by adjuvant therapy. Multidisciplinary evaluation is recommended to decide whether patients with stages I to IIIA NSCLC have resectable disease and to determine the most appropriate surgical procedure. The NCCN Guidelines now recommend biomarker testing for EGFR mutations in patients with completely resected stages IB to IIIA NSCLC to determine whether they are eligible for certain adjuvant targeted therapy. Previously, the NCCN Guidelines only recommended biomarker testing for eligible patients with advanced NSCLC.

This tumor board will discuss how to select the most appropriate therapy for patients with non-small cell lung cancer (NSCLC) using a case-based format. New targeted therapy regimens are being rapidly approved for patients with metastatic NSCLC and have been shown to improve outcomes for these patients.

This activity will address the increasing use of biomarker testing in the management of patients with non-small cell lung cancer, the factors affecting the selection of the appropriate tests, challenges of interpreting test results and communicating the results to patients, and new developments in biomarker testing.

The NCCN Guidelines for Lung Cancer Screening recommend criteria for selecting individuals for screening and provide recommendations for evaluation and follow-up of lung nodules found during initial and subsequent screening. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Lung Cancer Screening.

The rapid pace of updates to the NCCN Guidelines for Non-small Cell Lung Cancer makes it challenging for health care providers to stay informed about the newest recommendations, including side effects with these agents. Health care providers need to be aware of the latest NCCN recommendations to improve care for their patients with metastatic NSCLC.

The rapid pace of updates to the NCCN Guidelines for Non-Small Cell Lung Cancer makes it challenging for health care providers to stay informed about the newest recommendations. Health care providers need to be aware of the latest NCCN recommendations to improve care for their patients with metastatic NSCLC.

As a result of the therapeutic advances and clinical research affecting the management of patients with cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers.

Before a specific multidisciplinary treatment plan is recommended for an individual patient, multidisciplinary evaluation in tumor boards is often advised to ensure the patient receives the most appropriate treatment. The multidisciplinary team approach has been shown to improve outcomes in patients with lung cancer.